Class Action Filed Against Anavex Life Sciences Over Investor Claims
A New York law firm has filed a securities class action against Anavex Life Sciences, targeting the biotech firm and certain officers.
A securities class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) and certain of its officers, according to an announcement from Bronstein, Gewirtz & Grossman, LLC, a New York-based investor-rights law firm with a national practice.
The firm, which describes itself as a nationally recognized advocate for investor rights, is urging shareholders who suffered losses in connection with their Anavex holdings to take action. The lawsuit seeks financial recovery on behalf of affected investors, though specific allegations and alleged damages were not fully detailed in the firm's initial announcement.
Read more FTC Solar Amends Credit Agreement, Adjusts Loan Covenants →
Securities class actions of this type typically allege that a company or its executives made materially false or misleading statements that artificially affected the share price, causing harm to investors who bought shares during the relevant period. Investors who believe they qualify as class members are generally advised to consult legal counsel regarding deadlines to seek appointment as lead plaintiff.
Anavex Life Sciences is a clinical-stage biopharmaceutical company. Shareholders with potential claims are encouraged to review the complaint and act within court-imposed timeframes, which in federal securities cases are typically strict. Continue reading at Banking & Financial Services.
